Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71


Efficacy evaluation of an anti-caries varnish: protocol for a phase II randomised controlled trial.

Milgrom P, Tut O, Rothen M, Mancl L, Gallen M, Tanzer JM.

BMJ Open. 2017 Jun 30;7(6):e017866. doi: 10.1136/bmjopen-2017-017866.


Emissions of Selected Semivolatile Organic Chemicals from Forest and Savannah Fires.

Wang X, Thai PK, Mallet M, Desservettaz M, Hawker DW, Keywood M, Miljevic B, Paton-Walsh C, Gallen M, Mueller JF.

Environ Sci Technol. 2017 Feb 7;51(3):1293-1302. doi: 10.1021/acs.est.6b03503. Epub 2017 Jan 18.


Making Comfort Count: Using Quality Improvement to Promote Pediatric Procedural Pain Management.

Rosenberg RE, Klejmont L, Gallen M, Fuller J, Dugan C, Budin W, Olsen-Gallagher I.

Hosp Pediatr. 2016 Jun;6(6):359-68. doi: 10.1542/hpeds.2015-0240. Epub 2016 May 12.


Occurrence and distribution of brominated flame retardants and perfluoroalkyl substances in Australian landfill leachate and biosolids.

Gallen C, Drage D, Kaserzon S, Baduel C, Gallen M, Banks A, Broomhall S, Mueller JF.

J Hazard Mater. 2016 Jul 15;312:55-64. doi: 10.1016/j.jhazmat.2016.03.031. Epub 2016 Mar 16.


Monthly variation in faeces:blood concentration ratio of persistent organic pollutants over the first year of life: a case study of one infant.

Chen Y, McLachlan MS, Kaserzon S, Wang X, Weijs L, Gallen M, Toms LM, Li Y, Aylward LL, Sly PD, Mueller JF.

Environ Res. 2016 May;147:259-68. doi: 10.1016/j.envres.2016.02.017. Epub 2016 Feb 23.


Symptoms with betel nut and betel nut with tobacco among Micronesian youth.

Milgrom P, Tut OK, Gallen M, Mancl L, Spillane N, Chi DL, Ramsay DS.

Addict Behav. 2016 Feb;53:120-4. doi: 10.1016/j.addbeh.2015.10.011. Epub 2015 Oct 8.


Persistent organic pollutants in matched breast milk and infant faeces samples.

Chen Y, Wang X, Li Y, Toms LM, Gallen M, Hearn L, Aylward LL, McLachlan MS, Sly PD, Mueller JF.

Chemosphere. 2015 Jan;118:309-14.


Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S.

Lancet. 2014 Jun 21;383(9935):2127-35. doi: 10.1016/S0140-6736(14)60488-8. Epub 2014 Mar 19. Erratum in: Lancet. 2014 Nov 22;384(9957):1848.


[Treatment of colorectal cancer with unresectable metastasis with chemotherapy without primary tumor resection: analysis of tumor-related complications].

Cáceres M, Pascual M, Alonso S, Montagut C, Gallén M, Courtier R, Gil MJ, Grande L, Andreu M, Pera M.

Cir Esp. 2014 Jan;92(1):30-7. doi: 10.1016/j.ciresp.2013.04.015. Epub 2013 Oct 28. Spanish.


Areca use among adolescents in Yap and Pohnpei, the Federated States of Micronesia.

Milgrom P, Tut OK, Gilmatam J, Gallen M, Chi DL.

Harm Reduct J. 2013 Oct 17;10:26. doi: 10.1186/1477-7517-10-26.


Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.

Sastre J, Vidaurreta M, Gómez A, Rivera F, Massutí B, López MR, Abad A, Gallen M, Benavides M, Aranda E, Rubio ED; Spanish Cooperative Group for the Treatment of Digestive Tumors.

Clin Colorectal Cancer. 2013 Dec;12(4):280-6. doi: 10.1016/j.clcc.2013.06.001. Epub 2013 Sep 5.


Stage II disease, elderly patients, secondary neoplasms, and the MOSAIC trial.

Gallén M, Gallego R, Bellmunt J.

J Clin Oncol. 2013 Apr 20;31(12):1609. doi: 10.1200/JCO.2012.47.1854. Epub 2013 Mar 18. No abstract available.


Colorectal cancer survival: results from a hospital-based cancer registry.

Agüero F, Murta-Nascimento C, Gallén M, Andreu-García M, Pera M, Hernández C, Burón A, Macià F.

Rev Esp Enferm Dig. 2012 Dec;104(11):572-7.


Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.

Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Reboredo M, Manzano JL, Rivera F, Safont MJ, Montagut C, González E, Benavides M, Marcuello E, Cervantes A, Martínez de Prado P, Fernández-Martos C, Arrivi A, Bando I, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).

PLoS One. 2012;7(10):e47345. doi: 10.1371/journal.pone.0047345. Epub 2012 Oct 12.


Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer.

Salazar R, Navarro M, Losa F, Alonso V, Gallén M, Rivera F, Benavides M, Escudero P, González E, Massutí B, Gómez A, Majem M, Aranda E.

Clin Transl Oncol. 2012 Aug;14(8):592-8. doi: 10.1007/s12094-012-0846-7. Epub 2012 Jul 11.


Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

Sastre J, Maestro ML, Gómez-España A, Rivera F, Valladares M, Massuti B, Benavides M, Gallén M, Marcuello E, Abad A, Arrivi A, Fernández-Martos C, González E, Tabernero JM, Vidaurreta M, Aranda E, Díaz-Rubio E.

Oncologist. 2012;17(7):947-55. doi: 10.1634/theoncologist.2012-0048. Epub 2012 May 29.


Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function.

Morales-Barrera R, Bellmunt J, Suárez C, Valverde C, Guix M, Serrano C, Gallén M, Carles J.

Eur J Cancer. 2012 Aug;48(12):1816-21. doi: 10.1016/j.ejca.2012.04.002. Epub 2012 May 16.


Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Seshagiri S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J.

Nat Med. 2012 Jan 22;18(2):221-3. doi: 10.1038/nm.2609. Erratum in: Nat Med. 2012 Sep;18(9):1445. Somasekar, Seshagiri [corrected to Seshagiri, Somasekar].


First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors.

Oncologist. 2012;17(1):15-25. doi: 10.1634/theoncologist.2011-0249. Epub 2012 Jan 10.

Supplemental Content

Loading ...
Support Center